Kevin Chung
Known title: Chief Medical OfficerCIK: 0001949950
Kevin Chung's purchase track record
How the stock did after each of Kevin Chung's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
7
of 7 since April 5, 2022
Stock higher 6 months later
14%
3 months: 14%
Median 6-month return
-44.0%
3 months: -52.5%
Beat the S&P 500
14%
median -45.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/22/2025 | ICU | $8K | -61.9% | -69.5% | +6.8% |
| 5/20/2025 | ICU | $6K | -37.7% | -73.9% | +11.4% |
| 11/18/2024 | ICU | $8K | -17.3% | -44.0% | +1.2% |
| 9/30/2024 | ICU | $4K | -53.0% | -61.0% | -2.6% |
| 5/30/2023 | ICU | $6K | -52.5% | -11.0% | +8.3% |
| 5/18/2023 | ICU | $5K | -55.3% | -7.4% | +7.4% |
| 4/5/2022 | ICU | $7K | +0.5% | +1.9% | -16.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ICU | ▲ Buy | Grant | 7,202 | $0 | 7/1/2026 | View on chart |
| ICU | ▲ Buy | Grant | 15,000 | $0 | 2/6/2026 | View on chart |
| ICU | ▲ Buy | Open Market | 10,000 | $8K | 8/22/2025 | View on chart |
| ICU | ▲ Buy | Option Exercise | 5,000 | $0 | 7/1/2025 | View on chart |
| ICU | ▲ Buy | Open Market | 4,500 | $6K | 5/20/2025 | View on chart |
| ICU | ▲ Buy | Open Market | 4,250 | $8K | 11/18/2024 | View on chart |
| ICU | ▲ Buy | Open Market | 1,000 | $4K | 9/30/2024 | View on chart |
| ICU | ▲ Buy | Grant | 63,422 | $0 | 11/29/2023 | View on chart |
| ICU | ▲ Buy | Grant | 34,257 | $0 | 9/15/2023 | View on chart |
| ICU | ▲ Buy | Grant | 35,178 | $0 | 8/31/2023 | View on chart |
| ICU | ▲ Buy | Grant | 16,930 | $0 | 8/15/2023 | View on chart |
| ICU | ▲ Buy | Open Market | 5,093 | $2K | 5/30/2023 | View on chart |
| ICU | ▲ Buy | Open Market | 4,000 | $2K | 5/30/2023 | View on chart |
| ICU | ▲ Buy | Open Market | 2,300 | $1K | 5/30/2023 | View on chart |
| ICU | ▲ Buy | Open Market | 1,150 | $546 | 5/30/2023 | View on chart |
| ICU | ▲ Buy | Open Market | 7,500 | $5K | 5/18/2023 | View on chart |
| ICU | ▲ Buy | Grant | 44,322 | $0 | 4/6/2022 | View on chart |
| ICU | ▲ Buy | Open Market | 3,760 | $7K | 4/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
SeaStar Medical Adds ICD‑10‑PCS Codes for AKI Therapy
SeaStar Medical has released new ICD‑10‑PCS codes for its SCD therapy used in acute kidney injury. The codes allow hospitals to bill for the treatment, which could broaden usage. Earlier this week the company’s Chief Medical Officer, Kevin Chung, will speak at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium, highlighting the therapy’s pediatric applications. The company’s shares are trading near a key support level and have shown a recent volume spike.
SeaStar Medical Adds ICD‑10‑PCS Codes for AKI Therapy. SeaStar Medical has released new ICD‑10‑PCS codes for its SCD therapy used in acute kidney injury. The codes allow hospitals to bill for the treatment, which could broaden usage. Earlier this week the company’s Chief Medical Officer, Kevin Chung, will speak at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium, highlighting the therapy’s pediatric applications. The company’s shares are trading near a key support level and have shown a recent volume spike.